Not Yet RecruitingPhase 3

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

270 participantsStarted 2026-03-25

Plain-language summary

This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developing active multiple myeloma. The aim of this study is to find out whether linvoseltamab is better than daratumumab in delaying the development of MM. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Eastern Cooperative Oncology Group performance status score ≤1
✓. SMM diagnosis per IMWG criteria as defined in the protocol
✓. Meets HR-SMM criteria by 1 of the risk models as defined in the protocol

Exclusion criteria

✕. Evidence of myeloma-defining events attributable to the underlying plasma cell dyscrasia, as defined in the protocol
✕. Diagnosis of systemic light chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), plasma cell leukemia, or soft tissue plasmacytoma
✕. History of neurodegenerative condition, progressive multifocal leukoencephalopathy, or Central Nervous System (CNS) movement disorder
✕. History of a seizure within the 12 months of randomization
✕. Prior exposure to any approved or investigational treatments directed against a clonal plasma cell disorder (including but not limited to conventional chemotherapies, radiotherapy, immunomodulatory drugs, proteasome inhibitors, anti-CD38 antibodies). Ongoing treatment with other monoclonal antibodies (eg, infliximab, rituximab) or other treatments likely to interfere with study procedures or results, as described in the protocol.

What they're measuring

Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria

Timeframe: Up to 5 years

Biochemical PFS per IMWG criteria

Timeframe: Up to 5 years

Trial details

NCT IDNCT07393282

SponsorRegeneron Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2033-07-22

Contact for this trial

Clinical Trials Administrator

844-734-6643 clinicaltrials@regeneron.com

View on ClinicalTrials.gov More High Risk Smoldering Multiple Myeloma (HR-SMM) trials